BeOne Medicines Executive and Leadership Team

John Oyler, the Co-Founder, Chairman & Chief Executive Officer at BeOne Medicines, directs the overarching corporate strategy and long-term vision for the organization. Oyler architects the global expansion of oncology research, ensuring that the development of innovative cancer treatments remains aligned with the mission to reach patients across diverse international markets. By coordinating with the Board and senior leadership, the Chief Executive Officer maintains focus on the discovery and commercialization of therapies for hematologic malignancies and solid tumors. John Oyler drives the company toward sustainable growth while fostering a culture of scientific excellence. This leadership role involves managing complex stakeholder relationships and securing the resources necessary for large-scale pharmaceutical manufacturing. Through rigorous oversight of the entire corporate portfolio, the Chairman ensures that BeOne Medicines remains at the forefront of the biotechnology sector, consistently delivering value to patients and shareholders alike.

Anand Reddi, the Vice President, Chief of Staff To the Chairman and Chief Executive Officer at BeOne Medicines, manages the strategic agenda and executive communications for the top leadership. Reddi facilitates the implementation of corporate policies and ensures that the Chairman's vision is translated into actionable objectives across all departments. The Vice President, Chief of Staff To the Chairman and Chief Executive Officer monitors the progress of key pharmaceutical development programs, providing critical insights that inform high-level decision-making. Anand Reddi drives the alignment of internal teams with the company's mission to innovate in the field of oncology. This role involves managing complex stakeholder interactions and preparing the executive team for critical business milestones. By maintaining a clear focus on strategic priorities, the Vice President, Chief of Staff To the Chairman and Chief Executive Officer enhances the overall effectiveness of the leadership team, supporting the successful commercialization of treatments for hematologic malignancies and solid tumors.

Xiaobin Wu, the President & Chief Operating Officer at BeOne Medicines, manages the day-to-day operations and execution of the company's pharmaceutical development programs. Wu oversees the transition of research findings into scalable manufacturing processes, ensuring that the organization meets its production targets for cancer treatments. The President & Chief Operating Officer drives the operational strategy across global regions, focusing on the commercialization of therapies for solid tumors and hematologic malignancies. Xiaobin Wu coordinates with department heads to maintain high standards of quality and efficiency throughout the product lifecycle. By fostering operational excellence, the President & Chief Operating Officer supports the company's mission to expand access to effective cancer therapies worldwide. This leadership role involves managing large-scale budgets and human capital, ensuring that the organization remains agile in a competitive market. Through strategic oversight of internal functions, the President & Chief Operating Officer secures the company's ability to deliver life-saving medicines to patients.

Marcello Damiani, the Chief Technology Officer at BeOne Medicines, manages the digital infrastructure and technological frameworks supporting drug discovery and manufacturing processes. Damiani implements advanced data analytics and computational tools to accelerate the development of cancer therapies, ensuring that research teams possess the necessary technical capabilities to analyze complex biological data. The Chief Technology Officer oversees the integration of secure, scalable systems across global operations, facilitating seamless collaboration between laboratory researchers and clinical trial managers. Marcello Damiani drives the digital transformation of the pharmaceutical pipeline, optimizing workflows to reduce time-to-market for new treatments. By aligning technological investments with the broader corporate mission, the Chief Technology Officer supports the efficient production of medicines for solid tumors and hematologic malignancies. This role requires constant evaluation of emerging technologies to maintain a competitive edge in the biotechnology industry, ultimately enhancing the precision and efficacy of the company's therapeutic offerings.

Danielle Abatemarco, the Chief of Staff at BeOne Medicines, coordinates executive operations and facilitates communication across the leadership team to ensure organizational alignment. Abatemarco manages high-priority projects and strategic initiatives, acting as a central point of contact for cross-functional departments involved in the development of cancer treatments. The Chief of Staff optimizes internal processes, allowing the executive team to focus on the core mission of expanding access to effective therapies. Danielle Abatemarco drives the execution of corporate goals by monitoring progress on key milestones related to the manufacturing and commercialization of pharmaceutical products. This role involves synthesizing complex information for the Chairman and other senior leaders, enabling data-driven decision-making. By streamlining administrative and operational workflows, the Chief of Staff enhances the overall efficiency of the company, ensuring that resources are effectively allocated to support the research and development of treatments for hematologic malignancies and solid tumors.

Shiqi Chen, the Specialist, Chief Marketing Officer Site Management, Clinical Supply Chain at BeOne Medicines, directs the logistics and site management strategies required for successful clinical trials. Chen oversees the complex supply chain network, ensuring that essential cancer treatments reach clinical sites globally with precision and reliability. The Chief Marketing Officer Site Management, Clinical Supply Chain manages relationships with external partners and internal research teams to maintain a consistent flow of materials for studies targeting hematologic malignancies. Shiqi Chen drives the optimization of distribution channels, reducing lead times and ensuring compliance with international pharmaceutical standards. By coordinating site-specific requirements, the Chief Marketing Officer Site Management, Clinical Supply Chain supports the rapid advancement of the company's clinical pipeline. This role involves rigorous planning and real-time problem solving to mitigate supply chain risks, ultimately ensuring that patients participating in trials receive timely access to innovative therapies developed by the organization.

Wendy Shagena, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management at BeOne Medicines, directs the quality control protocols and vendor relationships essential for pharmaceutical manufacturing. Shagena ensures that all external partners adhere to strict regulatory standards, maintaining the integrity of the supply chain for cancer treatments. The Manager, Quality Assurance & Chief Marketing Officer, Vendor Management oversees the evaluation and selection of vendors, optimizing the procurement process to support the development of therapies for solid tumors. Wendy Shagena drives the implementation of quality management systems that guarantee the safety and efficacy of all products manufactured by the company. By managing vendor performance and compliance, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management mitigates operational risks and supports the company's commitment to excellence. This role involves continuous monitoring of production standards, ensuring that every stage of the manufacturing process aligns with the global mission to provide high-quality oncology care.

Mark Lanasa, the Senior Vice President, Chief Medical Officer, Solid Tumors at BeOne Medicines, directs the clinical research and medical strategy for the company's solid tumor portfolio. Lanasa oversees the design and execution of clinical trials, ensuring that the development of new cancer treatments meets rigorous scientific and safety standards. The Senior Vice President, Chief Medical Officer, Solid Tumors collaborates with regulatory bodies and medical experts to advance the company's pipeline toward commercialization. Mark Lanasa drives the interpretation of clinical data, providing the medical expertise necessary to validate the efficacy of innovative therapies. By leading the medical team, the Senior Vice President, Chief Medical Officer, Solid Tumors ensures that the organization remains focused on addressing the unmet needs of patients with solid tumors. This role involves constant engagement with the scientific community to refine treatment protocols and support the company's mission to expand access to effective cancer therapies worldwide.